Literature DB >> 28186677

Imaging porcine cardiac substrate selection modulations by glucose, insulin and potassium intervention: A hyperpolarized [1-13 C]pyruvate study.

Esben Søvsø Szocska Hansen1,2, Rasmus Stilling Tougaard1,3, Thomas Stokholm Nørlinger1, Emmeli Mikkelsen1, Per Mose Nielsen1, Lotte Bonde Bertelsen1, Hans Erik Bøtker3, Hans Stødkilde Jørgensen1, Christoffer Laustsen1.   

Abstract

Cardiac metabolism has received considerable attention in terms of both diagnostics and prognostics, as well as a novel target for treatment. As human trials involving hyperpolarized magnetic resonance in the heart are imminent, we sought to evaluate the general feasibility of detection of an imposed shift in metabolic substrate utilization during metabolic modulation with glucose-insulin-potassium (GIK) infusion, and thus the limitations associated with this strategy, in a large animal model resembling human physiology. Four [1-13 C]pyruvate injections did not alter the blood pressure or ejection fraction over 180 min. Hyperpolarized [1-13 C]pyruvate conversion showed a generally high reproducibility, with intraclass correlation coefficients between the baseline measurements at 0 and 30 min as follows: lactate to pyruvate, 0.85; alanine to pyruvate, 1.00; bicarbonate to pyruvate, 0.83. This study demonstrates that hyperpolarized [1-13 C]pyruvate imaging is a feasible technique for cardiac studies and shows a generally high reproducibility in fasted large animals. GIK infusion increases the metabolic conversion of pyruvate to its metabolic derivatives lactate, alanine and bicarbonate, but with increased variability.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  GIK; MRI; cardiac; hyperpolarization

Mesh:

Substances:

Year:  2017        PMID: 28186677     DOI: 10.1002/nbm.3702

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  6 in total

1.  Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies.

Authors:  Zihan Zhu; Xucheng Zhu; Michael A Ohliger; Shuyu Tang; Peng Cao; Lucas Carvajal; Adam W Autry; Yan Li; John Kurhanewicz; Susan Chang; Rahul Aggarwal; Pamela Munster; Duan Xu; Peder E Z Larson; Daniel B Vigneron; Jeremy W Gordon
Journal:  J Magn Reson       Date:  2019-02-01       Impact factor: 2.229

2.  Acute renal metabolic effect of metformin assessed with hyperpolarised MRI in rats.

Authors:  Haiyun Qi; Per M Nielsen; Marie Schroeder; Lotte B Bertelsen; Fredrik Palm; Christoffer Laustsen
Journal:  Diabetologia       Date:  2017-09-21       Impact factor: 10.122

3.  Hyperpolarized [1-13 C]pyruvate combined with the hyperinsulinaemic euglycaemic and hypoglycaemic clamp technique in skeletal muscle in a large animal model.

Authors:  Mads Bisgaard Bengtsen; Esben Søvsø Szocska Hansen; Rasmus Stilling Tougaard; Mads Dam Lyhne; Nikolaj Fibiger Rittig; Julie Støy; Niels Jessen; Christian Østergaard Mariager; Hans Stødkilde-Jørgensen; Niels Møller; Christoffer Laustsen
Journal:  Exp Physiol       Date:  2021-11-15       Impact factor: 2.858

4.  Hyperpolarized [1-13 C] pyruvate as a possible diagnostic tool in liver disease.

Authors:  Uffe Kjaergaard; Christoffer Laustsen; Thomas Nørlinger; Rasmus S Tougaard; Emmeli Mikkelsen; Haiyun Qi; Lotte B Bertelsen; Niels Jessen; Hans Stødkilde-Jørgensen
Journal:  Physiol Rep       Date:  2018-12

5.  High Intrarenal Lactate Production Inhibits the Renal Pseudohypoxic Response to Acutely Induced Hypoxia in Diabetes.

Authors:  Christoffer Laustsen; Kasper Lipsø; Jakob Appel Østergaard; Per Mose Nielsen; Lotte Bonde Bertelsen; Allan Flyvbjerg; Michael Pedersen; Fredrik Palm; Jan Henrik Ardenkjær-Larsen
Journal:  Tomography       Date:  2019-06

6.  Assessing the optimal preparation strategy to minimize the variability of cardiac pyruvate dehydrogenase flux measurements with hyperpolarized MRS.

Authors:  Kerstin N Timm; Andrew Apps; Jack J Miller; Vicky Ball; Cher-Rin Chong; Michael S Dodd; Damian J Tyler
Journal:  NMR Biomed       Date:  2018-07-24       Impact factor: 4.044

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.